Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Respiratory viral infections research, and SARS-CoV-2 detection and testing.
Workflow‑Based Information Management Framework for Multicenter Research Studies: Design and Development.
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.
Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.
Respiratory syncytial virus (RSV) vaccine effectiveness and antibody correlates of protection among older adults in the Community Vaccine Effectiveness (CoVE) observational study
Detection of SARS-CoV-2 Reinfections Using Nucleocapsid Antibody Boosting.
A framework for monitoring RSV prevention product effectiveness in the United States.
Ratio of Infections to COVID-19 Cases and Hospitalizations in the United States based on SARS-CoV-2 Seroprevalence Data, September 2021-February 2022.
Reply to "Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection".
Estimated US Trends in SARS-CoV-2 Spike Antibody Concentrations and Correlation to Risk of First-Time Infections Based on Blood Donations, 2022.
Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season.
Association Between Social Vulnerability and Infection-Induced SARS-CoV-2 Antibody Seroprevalence Among Children: United States, 2021-2022.
Respiratory syncytial virus (RSV) vaccine effectiveness and antibody correlates of protection among older adults in the Community Vaccine Effectiveness (CoVE) observational study
Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022.
Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season
Association of infection-induced antibody levels with risk of subsequent SARS-COV-2 reinfection among healthcare professionals, Rhode Island, 1 March 2020-17 February 2021.
Proportions of US Blood Donors With Serological Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections Who Reported Survey-Based Diagnosed Infections During July 2020-December 2022.
Complete genome sequence of a novel <i>Acinetobacter</i> spp. linked to an outbreak of sepsis following apheresis platelet transfusion.
Coronavirus Disease 2019 Symptoms by Immunity Status and Predominant-Variant Period Among US Blood Donors.
Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024.
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children.
Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness.
Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors.
Who Gets Sick From COVID-19? Sociodemographic Correlates of Severe Adult Health Outcomes During Alpha- and Delta-Variant Predominant Periods: September 2020-November 2021.
Long-Term Symptoms Associated With SARS-CoV-2 Infection Among Blood Donors.
What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
Administration of the GSK Respiratory Syncytial Virus Vaccine to Pregnant Persons in Error.
Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES–RECOVER Prospective Cohort Study
Differences in COVID-19 Outpatient Antiviral Treatment Among Adults Aged ≥65 Years by Age Group - National Patient-Centered Clinical Research Network, United States, April 2022-September 2023.
Spike and nucleocapsid antibody dynamics following SARS-CoV-2 infection and vaccination: Implications for sourcing COVID-19 convalescent plasma from routinely collected blood donations.
Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021.